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Abstract. Prostate cancer (PC) is the most common type of 
cancer among men. Aggressive and metastatic PC results in life-
threatening tumors, and represents one of the leading causes of 
mortality in men. Previous studies of atypical protein kinase C 
isoforms (aPKCs) have highlighted its role in the survival of 
cultured prostate cells via the nuclear factor (NF)-κB pathway. 
The present study showed that PKC-ι was overexpressed in PC 
samples collected from cancer patients but not in non-invasive 
prostate tissues, indicating PKC-ι as a possible prognostic 
biomarker for the progression of prostate carcinogenesis. 
Immunohistochemical staining further confirmed the associa-
tion between PKC-ι and the prostate malignancy. The DU-145 
and PC-3 PC cell lines, and the non-neoplastic RWPE-1 
prostatic epithelial cell line were cultured and treated with 
aPKC inhibitors 2-acetyl-1,3-cyclopentanedione (ACPD) and 
5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imid-
azole-4-carboxamide (ICA-1). Western blot data demonstrated 
that ICA‑1 was an effective and specific inhibitor of PKC‑ι and 
that ACPD inhibited PKC-ι and PKC-ζ. Furthermore, the two 
inhibitors significantly decreased malignant cell proliferation 
and induced apoptosis. The inhibitors showed no significant 
cytotoxicity towards the RWPE-1 cells, but exhibited cyto-
static effects on the DU-145 and PC-3 cells prior to inducing 
apoptosis. The inhibition of aPKCs significantly reduced the 
translocation of NF-κB to the nucleus. Furthermore, this inhi-
bition promoted apoptosis, reduced signaling for cell survival, 
and reduced the proliferation of PC cells, whereas the normal 
prostate epithelial cells were relatively unaffected. Overall, the 
results suggested that PKC-ι and PKC-ζ are essential for the 
progression of PC, and that ACPD and ICA-1 can be effec-
tively used as potential inhibitors in targeted therapy.
Introduction
The American Cancer Society estimates that 164,690 new 
cases of prostate cancer (PC) will be diagnosed in 2018. PC is 
the third leading cause of cancer-associated mortality among 
American men, following lung and colorectal cancer. It is 
estimated that ~1/7 men are diagnosed with the disease during 
their lifetime, with 1/39 succumbing to the disease (1).
The most common treatments for PC include radiation 
therapy, chemotherapy and hormone therapy. Radiation 
therapy is not always ideal as healthy living cells are damaged 
by the treatment, causing numerous side effects in patients. 
Hormone therapy requires surgical castration and the use of 
anti-androgens, which also have side effects and affect the 
patient's lifestyle (2). In addition to the side effects that follow 
hormone therapy, patients often become castration-resistant, 
meaning the cancer is no longer affected by the treatment (2). 
Once this occurs, chemotherapeutics, including docetaxel, are 
used. Docetaxel only increases a patient's survival rate by ~3 
months. This is largely due to resistance that develops within 
the cancer cells (3).
The protein kinase C (PKC) family of isozymes transduce 
signals and control other proteins through phosphorylation (4). 
The PKC family comprises 14 known isozymes, which are 
found in varying ratios in the cytoplasmic and membrane frac-
tion of cells depending on the type of tissue and its physiological 
state (5). PKC isozymes can be classified into three groups. 
Group I includes Ca2+-dependent isozymes: cPKC-α, cPKC-βl, 
cPKC-βll, and cPKC-γ. Isozymes in Group II (nPKC-δ, 
nPKC-ε, nPKC-η and PKC-θ) are Ca2+-independent. Group III 
includes the atypical (a)PKCs, including aPKC-ι (6), aPKC-ζ, 
aPKC-ζll (7) aPKC-µ (protein kinase D) and aPKC-ν (8), which 
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are insensitive to diacylglycerol and calcium and do not bind to 
or become activated by phorbol esters. PKC regulates cellular 
functions, metabolism and proliferation by phosphorylating 
proteins in response to transmembrane signals from hormones, 
growth factors, neuro-transmitters, and pharmacological 
agents. The activation of PKC by various agonists, including 
radiation, results in the altered transcription of a consider-
able number of genes. PKCs are involved in the day-to-day 
functioning of normal cells, however, they can cause several 
adverse effects when disrupted. PKC is the major receptor 
for tumor-promoting phorbol esters, however, the extent to 
which PKC is involved in cellular malignancy remains to be 
fully elucidated. Various studies have indicated that increased 
tumorigenicity results from either the dysregulation of PKC 
activity, changes in PKC concentration, or both (9-13).
PKC isozymes have been implicated in carcinogenesis, 
however, investigation of the functional significance of these 
enzymes in human cancer has been limited so far. PKC 
isozymes α, β, δ, ε, γ, η, ζ, ι, and µ are expressed in the normal 
and cancerous prostate (14). LNCaP cells are a widely used 
model for investigation of PC. Besides classical PKC-α, the 
novel PKC-δ is overexpressed in LNCaP cells and provokes 
phorbol ester-induced apoptosis. In PC-3 and DU-145 cells, 
PKC-δ is involved in the cell motility and invasion of prostate 
tumor cells (15,16). In addition, PKC-ε alongside Akt promotes 
matrix adhesion‑containing actin‑filaments and β-intergins in 
recurrent PC cells (15). In DU-145 cells, the downregulation 
of PKC-ε prevents apoptosis (16). Therefore, PKC-ε may be 
targeted for prostate therapy. Finally, the PKC-µ and PKC-ζ 
mammalian target of rapamycin (mTOR)/p70 S6 kinase 
pathway is associated with the progression of androgen-
dependent PC to androgen-independent PC (17-19). Therefore, 
understanding PKC isoforms in PC may contribute to possible 
novel diagnostic and therapeutic strategies.
PKCs is involved in tumor growth and formation when the 
levels of PKC are markedly altered (5). PKC-ι is a member of 
the PKC family located in chromosome 3 at 3q26.2, and is a 
human oncogene. PKCs can be overexpressed in various types 
of cancer, including ovarian, lung, head and neck cancer, and 
PC (20-22). Elevated levels of PKC-ι have been correlated with 
poorer prognosis. It was found that patients with lung cancer 
who had elevated levels of PKC-ι during the early stages 
were 10 times more likely to succumb to mortality from the 
disease, compared with those who had low levels of PKC-ι. 
PKC-ι is also involved in several oncogenic signaling path-
ways (23). For these reasons, the in vitro effects of two novel 
aPKC inhibitors, 5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-
4-methylcyclopentyl)-1H-imidazole-4-carboxamide (ICA-1) 
and 2-acetyl-1,3-cyclopentanedione (ACPD), on the normal 
RWPE-1 cell line, and the DU-145 and PC-3 PC cell lines, 
were investigated in the present study. ICA-1 has been shown 
to target PKC-ι, whereas ACPD has been shown to target 
PKC-ι and PKC-ζ (24,25).
The nuclear factor (NF)-κB signaling pathway is involved 
in cancer propagation and dissemination in several types of 
cancer, however, its involvement in PC remains to be fully 
elucidated. The inhibitor of NF-κB kinase (IKK) complex is 
comprised of IKKα and IKKβ, both of which are necessary for 
the activation of NF-κB. In the present study, it was hypoth-
esized that PKC-ι acts on IKKα/β, causing the release and 
translocation of NF-κB. Inhibition of this pathway following 
treatment with ICA-1 is expected allow normal apoptosis to 
take place with minimal effect on RWPE-1 cells, but with 
more marked effects in DU-145 and PC-3 cells.
The results of the present study showed a correlation 
between the presence of PKC-ι and PC. It also revealed the 
efficacy of ACPD and ICA‑1 on PKC‑ι and indicated the role 
of PKC-ι in the survival of PC. Cumulatively, the results led 
to the conclusion that the detection of PKC-ι may be used as a 
biomarker of prostate carcinogenesis and that PKC-ι inhibition 
may be an alternative therapy in patients with PC.
Materials and methods
ICA‑1 was synthesized by Therachem Research Medilab 
(Jaipur, India) and ACPD was purchased from Sigma‑Aldrich; 
EMD Millipore (Billerica, MA, USA). The inhibitors were 
dissolved in sterile distilled water prior to use. Dulbecco's 
phosphate-buffered saline without Mg2+ and Ca2+ (DPBS) 
was purchased from the American Type Culture Collection 
(Manassas, VA, USA). Trypsin-ethylenediaminetetraacetic 
acid (EDTA) solution was purchased from Thermo Fisher 
Scientific, Inc. (Waltham, MA, USA). Polyclonal primary 
antibodies were purchased from the following companies: 
Anti-PKC-ι mouse monoclonal (cat. no. 610176) and B-cell 
lymphoma 2 (Bcl-2; cat. no. 610538) from BD Transduction 
Laboratory (Lexington, KY, USA). PKC-ζ (cat. no. sc-17781), 
NF-κB p65 (cat. no. sc-372-G), inhibitor of NF-κBα 
(IκBα; cat. no. sc-1643), phosphorylated (phospho) IκBα 
(cat. no. sc-8404) β-actin (cat. no. sc-1616) goat polyclonal, 
PKC-α (cat. no. sc-8393) mouse monoclonal, cytochrome c 
(cat. no. sc-13156), survivin (cat. no. sc-17779) and caspase-3 
(cat. no. sc-7272) from Santa Cruz Biotechnology Co., Ltd. 
(Santa Cruz, CA, USA), phosphorylated phosphatase and 
tensin homolog (PTEN; S380; cat. no. 9551), phosphory-
lated AKT (S473; cat. no. 4059S), phosphorylated IKKα/β 
(S176/180; cat. no. 2697), poly (ADP-ribose) polymerase 
(PARP; cat. no. 9532) and cleaved-PARP (cat. no. 9185) 
from Cell Signaling Technology Inc. (Danvers, MA, USA). 
β-catenin (cat. no. ab16051) from Abcam (Cambridge, 
MA, USA). Secondary antibodies were purchased from the 
following companies: Horseradish peroxidase (HRP) goat 
x mouse IgG (cat. no. JGM035146), HRP goat x rabbit IgG 
(cat. no. JGZ035144) from Accurate (Westbury, NY, USA); 
HRP bovine anti-goat IgG (cat. no. sc-2350 from Santa Cruz 
Biotechnology, Inc.. The RWPE-1 (ATCC® CRL-11609™) 
epithelial cells and DU-145 (ATCC® HTB-81™) human pros-
tate carcinoma cells were purchased from the American Type 
Culture Collection. The PC‑3 cells were acquired from Moffitt 
Cancer Center (Tampa, FL, USA).
Prostate tissue analysis. The protein for western blot analysis 
was extracted from human biopsy-derived benign prostate 
hyperplasia (BPH) tissues obtained from the Cooperative 
Human Tissue Network (Southern Division) at the University 
of Alabama (Birmingham, AL, USA). For the purposes 
of the present study, BPH was defined as a non-cancerous 
enlargement of the prostate gland. The BPH tissue samples 
were obtained from men of varying ages (57-80 years old) 
with a mean age of 67.6 years. Protein extraction from the 
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fresh-frozen radical prostatectomy samples of patients with 
PC were obtained during surgery performed at the James A. 
Haley Veterans Hospital (Tampa, FL, USA) between May and 
August 2007. All patients provided informed consent as part of 
a clinical protocol approved by the Institutional Review Board 
(IRB no. 103023) of the University of South Florida (Tampa, 
FL, USA). The samples were placed on ice immediately 
following prostatectomy and were frozen in liquid nitrogen 
within 30-60 min post-prostatectomy. The prostate tissues 
(0.5-1 g) were re-suspended and sonicated in 2 ml homogeniza-
tion buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 
0.1% Tween-20, 1 mM ethylenediamine-tetraacetic acid, 2 mM 
ethylene glycol bis(β-aminoethyl ether)-N,N,N',N',-tetraacetic 
acid, 0.1 mM orthovanadate, 1 mM NaF, 2 mM phenyl-methyl-
sulfonly fluoride, 2.5 µg/ml leupeptin, 1 mM dithiothreitol and 
0.15 U/ml aprotinin. The suspension was sonicated for three 
15 sec cycles on ice. The prostate tissue suspensions or cell 
lysates were centrifuged at 40,000 g for 30 min at 4˚C to obtain 
cell extracts. The proteins were quantified according to the 
Bradford method (26). Tissue extracts containing equal quanti-
ties of protein in each lane were run on 10% SDS-PAGE gels 
according to Laemmli (27) and the proteins were transblotted 
on nitrocellulose membrane according to Towbin et al (28). The 
tissue lysates (100 µg) were used for western blot analysis with 
antibodies against PKC-α (10 µg, 1:500 dilution), PKC-ι (5 µg, 
1:4,000 dilution) and β-actin (10 µg, 1:500 dilution) and incu-
bated for a duration of 1 h at room temperature. The secondary 
antibodies, obtained from Accurate (cat. nos. JGM035146 and 
JG2035744) were used at a dilution of 1:15,000 (1 µg) and 
incubated for 2 h at room temperaure. The blots were subjected 
to chemiluminescence and results were captured on X‑ray film 
and developed by machine. Observable bands were scanned 
and quantified by densitometry analysis. The specimens used 
were from 10 patients with PC (one core with adenocarcinoma 
from each patient), eight patients with high grade prostate 
intraepithelial neoplasma (HGPIN; 1 core with HGPIN from 
each patient) and nine patients with BPH (1 core with from each 
patient), comprising a total of 27 samples. Samples obtained 
from cell cultures and examined by western blot analysis and 
were visualized digitally by the Protein Simple (San Jose, CA, 
USA) FlourChem system and analyzed with the accompanying 
alpha viewer software.
Immunohistochemical staining. For immunohistochemistry 
(IHC), de‑identified, archival, unstained sections of full‑core 
prostate needle biopsies (PNBs) were used, which were obtained 
for diagnostics in the systematic PC screening program at the 
James A. Haley Veterans Administration Medical Center. The 
PNB specimens examined were from 10 patients with PC 
(1 core with adenocarcinoma from each patient), eight patients 
with HGPIN (1 core with HGPIN from each patient) and nine 
patients with BPH (1 core with from each patient), comprising 
a total of 27 samples. Following the deparaffinization of the 
sections, and citrate microwave antigen retrieval, blocking 
was performed. For the detection of PKC-α, the sections 
were incubated with monoclonal anti-PKC-α antibody (1:100 
dilution; BD Transduction Laboratories) for 60 min at room 
temperature, followed by washing and detection with the 
‘EnVision’ detection system using mouse IgG polymer and 
DAB chromogen. For the detection of PKC-ι, separate sections 
were subsequently incubated overnight with purified mouse 
monoclonal anti-PKC-ι (1:200 dilution; BD Transduction 
Laboratories), followed by washing and a subsequent 30-min 
incubation at room temperature with 1:200 rat anti-mouse 
IgG2b. Final detection was performed using DAB chromogen. 
All sections were examined for PKC-α and PKC-ι and scored 
using the Allred semi-quantitative scoring system (29). The 
Allred score is a composite of the percentage of cells stained 
and the intensity of their staining. The percentage of cells 
stained, termed the proportion score, is classified between 0 
and 5. The intensity of the cells stained is termed the inten-
sity score and it is rated as 1, 2 or 3; thus, composite scores 
range between 0 and 8, with 0 being the lowest and 8 being 
the maximum score. The adenocarcinoma glands, glands with 
HGPIN, BPH glands, and stromal cells were scored separately 
using a microscope (Olympus, Tokyo, Japan).
Cell culture. The cells were grown as a monolayer in a T25 
tissue culture flask with 5 ml of growth medium and were 
maintained in a 37˚C incubator with 5% CO2. The E-MEM 
and F-12 growth media were obtained from American Type 
Culture Collection. The medium was supplemented with 
10% fetal bovine serum (FBS) and a mix of the antibiotics 
penicillin (10,000 IU) and streptomycin (10,000 µg/ml) in a 
100X concentration purchased from Corning Life Sciences 
(Tewksbury, MA, USA).
Cell proliferation assay. The RWPE-1, DU-145 and PC-3 
cells were cultured in T25 cell culture flasks with 20,000 cells 
seeded into each. The flasks were treated with either ICA‑1 or 
ACPD at doses of 1, 5, and 10 µM, in addition to an untreated 
control set for each. The treatment was repeated over the 
course of 72 h and samples were taken at 24-h intervals. The 
cells were trypsinized and placed into a 1.5 ml microcentrifuge 
tube at intervals of 24, 48, and 72 h. The tubes were inverted 
gently to maintain solution homogeneity and cell numbers 
were measured using a Cell Scepter counter (EMD Millipore).
4‑[3‑(4‑iodophenyl)‑2‑(4‑nitropheny))‑2H‑5‑tetrazolio]‑1,3‑
benzene disulfonate (WST‑1) assay for cell viability and 
cytotoxicity. The WST-1 assay (in vitro) was performed by 
culturing ~4x103 cells/well (RWPE-1, DU-145 and PC-3 cells) 
in a 96-well plate. After 24 h, fresh media were supplied 
(200 µl/well) and the cells were treated with either an equal 
volume of sterile water (vehicle control) or with 10 µM of 
ICA‑1 or 10 µM of ACPD, which was identified as the optimal 
working concentration for the PC cell lines for the two inhibi-
tors. Additional doses were supplied every 24 h during a 3-day 
incubation period. At the end of day 3, media were removed and 
fresh media (100 µl) were added with WST-1 reagent (10 µl) 
to each well. The absorbance was measured at 450 nm every 
1 h up to 8 h using the Synergy HT microplate reader from 
Biotek Instruments, Inc., (Winooski, VT, USA). The detailed 
procedure was performed as described by Ratnayake et al (30).
Cell sub‑fractionation. The DU-145 and PC-3 cells were 
cultured in a T25 cell culture flasks (20,000 cells seeded into 
each). The flasks were treated with either ICA‑1 or ACPD at a 
dose 10 µM, with an untreated control set for each. The treat-
ment was repeated over the course of 72 h and samples were 
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taken at 24-h intervals. At 30 min prior to harvesting, the cells 
were exposed to 10 nM of tumor necrosis factor (TNF)-α. 
The NE-PER Nuclear and Cytoplasmic Extraction kit from 
Thermo Fisher Scientific, Inc. was used to harvest the proteins 
and separate the nuclear protein from the cytoplasmic protein.
Flow cytometry for the analysis of apoptosis. The DU-145 
and PC‑3 cells (40,000 cells/flask) were cultured in a T25 
cell culture flasks. The flasks were treated with either ICA‑1 
or ACPD at a dose 10 µM, with an untreated control set for 
each. After 24 h, the media were removed and dead cells 
were collected by centrifugation using 350 x g for 4 min at 
4˚C. The cells were washed twice with ice‑cold DPBS (1X) 
prior to lifting with trypsin and trypsin was neutralized with 
an equal volume of media. The cells were then combined 
with the collected dead cells and washed twice with ice-
cold DPBS (1X). A PE Annexin V apoptosis detection kit 
(BD Biosciences, Pharmingen, San Jose, CA, USA) was used 
to detect the apoptosis according to the detailed protocol 
provided by BD Pharmingen. The BD Accuri™ C6 Plus 
personal flow cytometer instrument was used to analyze the 
samples. Three replicate experiments were performed.
Statistical analysis. All values are presented as the mean ± stan-
dard deviation (n=3, where n is a single trial and each trial 
contained 9-24 replicates). Statistical analysis was performed 
with Student's t-test or one-way analysis of variance followed 
by Tukey's multiple comparison tests using the ‘VassarStats’ 
web tool (vassarstats.net) for statistical analysis. P≤0.05 was 
considered to indicate a statistically significant difference.
Results
The association between the absence of PKC-ι in BPH tissue 
and its robust presence in PC is shown in Fig. 1. PKC-ι was 
abundant in all PC tissues. PKC-α (positive control PKC) 
and PKC-ι were identified in western blot analysis by bands 
with molecular weights of 80 and 74 kDa, respectively, which 
corresponded to the immunoreactive signal obtained from 
U-373MG glioma cells, which contain PKC-ι and PKC-α 
(data not shown). The western blot controls for PKC-α did not 
show a pattern of expression specific to BPH, or malignant 
prostate tumors. β-actin was used as the internal control to 
ensure equal quantities of protein loaded in to each well of 
the SDS-PAGE gel. A 100-fold increase in PKC-ι immunore-
activity was detected in PC tissue when compared with BPH 
tissue (Fig. 1A and B). The level of PKC-ι in the BPH tissue 
differed significantly from that in the PC tissue (P=0.00048). 
This demonstrated that PKC-ι was significantly overexpressed 
in PC tissues compared with BPH tissues.
Subsequently, IHC was performed to investigate compara-
tively the tissue distribution and intracellular localization 
of PKC-ι and PKC-α. The IHC data showed that PKC-α 
was expressed in the stromal cells but showed minimal to 
no expression in the majority of the BPH (Fig. 2A), HGPIN 
(Fig. 2B) or PC (Fig. 2C) glands. In only one case did the PC 
glands show moderate expression of PKC-α. In that case the 
PC glands expressing PKC-α were Gleason pattern 4 (Table I), 
which may explain the increase of PKC-α.
By contrast, the expression of PKC-ι was noted in all 
glands, with a proportion score of 5 in the majority of cases 
(Table I and Fig. 2D-F), however, the intensity of staining was 
more marked in the PC glands with Allred scores of +8 and +7 
(Table I and Fig. 2F), compared with that in the BPH glands 
(Fig. 2D) and glands with HGPIN (Table I and Fig. 2E). The 
BPH glands showed similar weak staining in samples obtained 
from patients with and without prostatic adenocarcinoma. The 
stromal cells showed weak to moderate staining in samples 
with and without adenocarcinoma. PKC-ι was present at low 
levels in a comparative number of the BPH samples, however, 
the intensity was markedly increased in the adenocarcinoma 
samples, resulting in higher composite scores. Overall, the IHC 
Figure 1. Expression of PKC-α and PKC-ι in prostate tissues. Tissue extracts (100 µg) of (A) BPH and (B) PC were immunoblotted for PKC-α and PKC‑ι. All 
patient tissues were maintained in liquid nitrogen and processed the same day of collection. BPH tissues showed minimal to no expression of PKC‑ι. PC tissues 
showed overexpression of PKC‑ι compared to BPH tissues (*P=0.00048). Western blot analysis for β-actin demonstrated equal loading of each sample. Three 
trials were performed in triplicate. BPH, benign prostate hyperplasia; PC, prostate cancer; PKC, protein kinase C; N, normal; M, malignant.
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data from the PNB specimens confirmed the higher expression 
of PKC-ι in PC detected in the western blot analysis from fresh 
frozen excisional clinical prostate tissue specimens.
To establish whether ACPD or ICA-1 affected PKC-ι 
and PKC-ζ, their protein levels were determined by western 
blot analysis. In the malignant cells (DU-145 and PC-3), 
Figure 2. Immunohistochemical staining of PKC-α and PKC‑ι in BPH, HGPIN and PC. Tissue was stained with PKC‑α antibody as a control for PKC‑ι 
staining. Results show PKC‑ι staining in (A) BPH, (B) HGPIN, and (C) PC tissue. PKC‑α staining is shown in (D) BPH glands, (E) glands with HGPIN, and 
(F) PC glands. Tissues examined comprised BPH (n=9), HGPIN (n=8) and PC tissues (n=10). Magnification for all micrographs was x400. Three experi-
ments were performed in triplicate. BPH, benign prostate hyperplasia; HGPIN, high grade prostate intraepithelial neoplasma; PC, prostate adenocarcinoma; 
PKC, protein kinase C.
Table I. PKC-α and PKC‑ι staining of glands and stroma of patients with BPH, HGPIN and prostate adenocarcinoma.
 Staining (No. of cases)a
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------
Total cases PKC-α 8+ 7+ 6+ 5+ 4+ 3+ 2+ 1+ 0
BPH Glands 0 0 0 0 0 0 5 0 4
9 Stroma 0 1 2 5 1 0 0 0 0
HGPIN Glands 0 0 0 0 0 0 3 0 5
8 Stroma 0 1 3 4  0 0 0 0 0
Adenocarcinoma Glands 0 0 1 0 1 0 4 0 4
10 Stroma 0 1 4 2 1 0 2 0 0
 Staining (No. of cases)a
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------
Total cases PKC‑ι 8+ 7+ 6+ 5+ 4+ 3+ 2+ 1+ 0
BPH Glands 0 2 7 0 0 0 0 0 0
9 Stroma 0 0 0 2 4 2 1 0 0
HGPIN Glands 1 3 3 1 0 0 0 0 0
8 Stroma 0 0 0 0 3 4 1 0 0
Adenocarcinoma Glands 9 1 0 0 0 0 0 0 0
10 Stroma 0 0 0 3 5 2 0 0 0
aStaining based on the Allred score (26). PKC, protein kinase C; BPH, benign prostate hyperplasia; HGPIN, high grade prostate intraepithelial 
neoplasma; PC, prostate adenocarcinoma.
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there was an abundance of PKC-ι (Fig. 3) compared with the 
normal cells (RWPE-1). There was a marginal difference in 
the RWPE cells, however, neither drug reduced the levels of 
PKC-ι significantly (P=0.077). The effects were more marked 
in the DU-145 cells. ICA-1 inhibited PKC-ι and, following 
3 days of treatment, there was a decrease of 64% (P=0.01) 
in PKC-ι. Following 3 days of treatment with ACPD, which 
inhibits PKC-ι and PKC-ζ, there was an average decrease of 
51% (P=0.018) in PKC-ι. In the PC-3 cells, there was a 40% 
(P=0.028) decrease in PKC-ι following treatment with ICA-1 
and a 37% (P=0.036) decrease in PKC-ι following treatment 
with ACPD. ICA‑1 had no significant effect on the levels of 
PKC-ζ in any of the cell lines, whereas ACPD had a significant 
effect, reducing the levels of PKC-ζ by 23% (P≤0.05), in the 
PC-3 cells only.
To determine whether ICA-1 or ACPD induced apop-
tosis, the apoptotic markers caspase-3, Bcl-2, PARP, cleaved 
PARP, survivin and cytochrome c were used to detect 
ongoing apoptosis in the cell lines (Fig. 3). In all three cell 
lines treated with ICA-1 and ACPD, there was a measurable 
increase in apoptosis. Following ICA-1 treatment for 72 h, the 
RWPE‑1 control line showed no significant change in either 
cytochrome c or survivin. Following treatment with ACPD 
for 72 h, the RWPE‑1 cells showed no significant change in 
Figure 3. Effects on PKC‑ι regulation and apoptosis. Effects on PKC‑ι and apoptosis were examined following inhibition of PKC‑ι with either ICA‑1 (10 µM) or 
ACPD (10 µM) for 72 h with respect to their controls. Protein expression of PKC‑ι, PKC‑ζ, caspase 3, Bcl-2, PARP, cytochrome c, and survivin in the RWPE-1 
cell line and the DU-145 and PC-3 malignant cell lines. A total of 35 µg protein was loaded into each well and results were normalized by β-actin. Three trials 
were performed in triplicate. Densitometry bar graphs show the percentage change of the treated sample with respect to their controls (mean ± standard devia-
tion). *P≤0.05, vs. control. PKC, protein kinase C; Bcl‑2, B‑cell lymphoma 2; PARP, poly (ADP‑ribose); ACPD, polymerase; 2‑acetyl‑1,3‑cyclopentanedione; 
ICA-1, 5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide. 
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cytochrome c or in survivin. By contrast, the DU-145 cell 
line showed a more substantial change, with an almost 3-fold 
increase in cytochrome c and a reduction in survivin by 50% 
following treatment of ICA-1. Following treatment with ACPD 
for 72, the DU-145 cells showed ~400% (P<0.001) increase in 
cytochrome c and a 50% (P=0.015) decrease in survivin. In 
the PC-3 cells treated with ICA-1, there was a 2-fold increase 
in cytochrome c (P=0.011) and a 40% decrease in survivin 
(P=0.028). The PC-3 cells treated with ACPD showed a 150% 
(P=0.013) increase in cytochrome c and a 35% decrease in 
survivin (P=0.042). The levels of caspase-3 and cleaved-PARP 
were significantly increased and those of Bcl‑2 and total PARP 
were significantly reduced upon inhibitor treatment in the PC 
cell lines. All cell lines were also probed with β-actin to ensure 
equal loading between lanes.
The effects of ICA-1 (10 µM) and ACPD (10 µM) on 
cell proliferation were also determined (Fig. 4A-C). There 
was a noticeable but statistically insignificant effect of the 
inhibitors ICA-1 and ACPD on the RWPE-1 cell line. Both 
inhibitors retained >90% of the cell population present in 
the untreated RWPE-1 cells (Fig. 4A). By contrast, there 
was a substantial decrease in the population of DU-145 cells 
treated with the inhibitors ICA‑1 (P≤0.01) and ACPD (P≤0.01) 
(Fig. 4B). The PC-3 cells showed a similar trend of population 
decline following treatment with ICA-1 (P=0.01) and ACPD 
(P=0.0052) (Fig. 4C).
To determine the in vitro cytotoxicity of ICA-1 and ACPD 
on normal and malignant cell lines, a WST-1 assay was 
performed. ICA-1 and ACPD demonstrated no significant 
cytotoxicity towards the normal prostate epithelial RWPE-1 
cell line (Fig. 4D). As shown in Fig. 4E and F, ICA-1 exhibited 
significant cytotoxicity (P≤0.05) on the two metastatic prostate 
cancer cell lines (DU-145 and PC-3). These results indicated 
that ICA-1 and ACPD appeared to be cytostatic more than 
cytotoxic in the time range assessed, thereby retarding PC cell 
growth and proliferation.
Figure 4. Effects of ICA-1 or ACPD on cell populations in a 72-h period. Populations of cells under normal conditions (red) and under treatment with either 
10 µM ICA-1 (blue) or 10 µM ACPD (yellow) in (A) RWPE-1, (B) DU-145, and (C) PC-3 cell lines. Effects of ICA-1 and ACPD on in vitro cytotoxicity over 8 h 
were measured by absorbance in nm under normal conditions (red) and under the effects of either 10 µM ICA-1 (blue) or 10 µM ACPD (yellow), in (D) RWPE-1, 
(E) DU-145, and (F) PC-3 cell lines. There were 24 replicates per sample performed over three trials. ACPD, polymerase; 2-acetyl-1,3-cyclopentanedione; 
ICA-1, 5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide.
Figure 5. Flow cytometric analysis of PE Annexin V staining for prostate 
cancer cells. Graphs show fluorescent emission of PC‑3 cells in the (A) control, 
(B), ICA-1- and (C) ACPD-treated groups, and DU-145 cells in the (D) con-
trol, (E) ICA-1- and (F) ACPD-treated groups. Cells were incubated with PE 
Annexin V (x-axis) against 7AAD (y-axis). Cells were treated with ICA-1 and 
ACPD with respective IC50 concentrations for 24 h and 50,000 events were 
analyzed and recorded to obtain FL3-A (PE-Annexin V), vs. FL-2A (7-AAD). 
Three experiments were performed with 24 replicates and representative 
plots are shown. ACPD, polymerase; 2-acetyl-1,3-cyclopentanedione; ICA-1, 
5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-
4-carboxamide; 7AAD, 7-amino-actinomycin; Ctrl, control.
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As shown in Fig. 5, flow cytometric analysis of apoptosis 
showed that PC-3 viability decreased from 91.8% (Fig. 5A) 
to 60.8% following ICA-1 treatment (Fig. 5B) and 60.9% 
following ACPD treatment (Fig. 5C). Early apoptosis increased 
from 6.8% (Fig. 5A) to 37.3 and 36.3% following ICA1 and 
ACPD treatments, respectively. By contrast, the DU-145 
cells showed a marginally lower response, in which viability 
decreased from 97.9% (Fig. 5D) to 89% following ICA-1 treat-
ment (Fig. 5E) and 85.5% following ACPD treatment (Fig. 5F). 
Early apoptosis increased from 0.9% (Fig. 5D) to 3.4 and 2.6% 
following ICA-1 and ACPD treatments, respectively (Fig. 5E 
and F). The late stage of apoptosis significantly increased from 
1.2% (Fig. 5D) to 7.6 and 12% for ICA-1 and ACPD treatments, 
respectively, in the DU-145 cell line (Fig. 5E and F).
Subsequently, the present study determined whether ICA-1 
or ACPD affected cell survival by inhibiting the transloca-
tion of NF-κB from the cytoplasm to the nucleus (Fig. 6). 
Following exposure to TNF-α, the protein levels of NF-κB 
were measured in the nucleus and the cytosol of DU-145 and 
PC-3 cells. Following treatment with ICA-1, there was a 5-fold 
decrease in nucleic NF-κB in the DU-145 cells (P=0.02) and a 
3-fold decrease of nucleic NF-κB in the PC-3 cells (P=0.025), 
compared with the untreated samples. With ACPD, there was 
a 1.5-fold decrease in nucleic NF-κB (P=0.046) in the DU-145 
cells and a 40% decrease in NF-κB (P=0.028) in the PC-3 
cells, compared with the untreated samples (Fig. 6). In addi-
tion, the phosphorylation of IKKαβ (S176/180) and IκBα (S32) 
were examined, both of which reduced significantly (P≤0.05) 
Figure 6. Effects of 10 µM ICA-1 and 10 µM ACPD on NF-κB translocation in RWPE-1, DU-145, and PC-3 cells. Protein expression of NF-κB p65 is shown in 
nuclear and cytoplasmic cell fractions following 72 h of treatment. Cells were exposed to 10 nM of TNF-α 30 min prior to harvest to induce NF-κB transloca-
tion. Other targets in the proposed pathway and targets known to be affected by PKC‑ι activation were assessed, including pIKKα/β, IKKα/β, pIκBα, IκBα, 
β-catenin, pPTEN, and pAKT. A total of 50 µg protein was loaded into each well and the results were normalized by β-actin. Three trials were performed 
in triplicate. Densitometry bar graphs are shown as the percentage change of the treated sample with respect to their controls (mean ± standard deviation). 
*P≤0.05, vs. control. NF‑κB, nuclear factor-κB; IκBα, inhibitor of NF-κBα; IKK, IκBα kinase; PTEN, phosphatase and tensin homolog; p, phosphorylated; 
ACPD, polymerase; 2-acetyl-1,3-cyclopentanedione; ICA-1, 5-amino-1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide.
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following inhibitor treatments in the two PC cell lines, which 
confirmed a reduction of NF‑κB translocation to the nuclei. 
The phosphorylation of PTEN (S380) and AKT (S473) also 
decreased significantly (P≤0.05) in the two PC cell lines, indi-
cating that the AKT pathway also slowed down upon inhibitor 
treatment.
Discussion
There has been increased interest in the status of aPKC-ι, which 
does not contain a Ca2+‑binding region, has one zinc finger‑like 
motif, and is the human homolog of the mouse PKC-λ (31). 
Eder et al (32) provided evidence for the role of PKC-ι in cell 
proliferation by demonstrating that increased protein levels of 
PKC-ι were associated with increased protein expression of 
cyclin E and proliferation in ovarian cancer. Eder et al (32) 
demonstrated in non-serous ovarian cancer that increased 
protein levels of PKC-ι markedly decreased overall survival 
rate. PKC-ι is critical for non-small cell lung cancer prolifera-
tion in vivo via activation of the Ras-related C3 botulinum toxin 
substrate 1 (Rac1)/Rac1-activated kinase/mitogen-activated 
protein kinase kinase 1,2/extracellular signal-regulated kinase 
1,2 signaling pathway, which has been implicated in tumor cell 
proliferation, indicating PKC-ι as an oncogene in human non-
small cell lung cancer (20,23). Additionally, the importance 
of PKC-ι is further recognized due to its exclusive association 
with transformed phenotype of human melanomas in vivo and 
in vitro (33), its overexpression in human non-small lung cancer 
cell lines and cholangiocarcinoma (34), and its presence in the 
transformed growth of the human lung adenocarcinoma A549 
cell line in vitro and tumorigenicity in vivo (20). Our previous 
study also highlighted the exclusive association of PKC-ι with 
the transformed phenotype of glioma and meningioma (35). 
However, the linkage between the PKC family of proteins and 
PC remains to be fully elucidated.
The results of the western blot analysis demonstrated 
that the PKC-ι protein was overexpressed in all PC tissues, 
but not in BPH tissues (P=0.00048). Furthermore, the IHC 
results demonstrated increased PKC-ι staining intensity 
in PC glands compared with BPH glands and glands with 
HGPIN. The BHP glands showed weak staining of PKC-ι, 
similar to samples obtained from patients with and without 
prostatic adenocarcinoma. The stromal cells showed weak 
to moderate staining of PKC-ι in samples with and without 
adenocarcinoma. It is possible that the reduced categorical 
expression of PKC-ι observed in the comparison between 
malignant and BPH tissues may be associated with the antigen 
retrieval methodology of the IHC process in formalin‑fixed, 
archival specimens. The observation of marked and consistent 
expression of PKC-ι in all PC specimens and certain HGPIN 
specimens is significant, as it may allow the prediction of the 
proportion of HGPIN patients, estimated to be up to 50%, who 
progress to clinical PC. The fact that benign prostatic acini 
in patients with PC do not significantly express PKC‑ι further 
underscores the histopathological dichotomy of the BPH and 
PC pathways. Finally, if PKC-ι is demonstrated to have be 
significant in prostate carcinogenesis, it may offer an oppor-
tunity to target PKC-ι in HGPIN patients for the prevention of 
PC. The results of the present study suggested that PC showed 
a higher dependency on PKC-ι compared with non-cancerous 
prostate tissue. The increase in the expression of PKC-ι may 
be due to gene amplification or genetic duplication of PKC‑ι. 
Figure 7. Details the proposed pathway where PKC‑ι acts on IKK α/β to release NF-κB, causing IKK to be degraded and allowing NF-κB to translocate to the 
nucleus. PKC, protein kinase C: NF-κB, nuclear factor-κB; IκBα, inhibitor of NF-κBα; IKK, IκBα kinase.
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Previous studies have shown that chromosome 3q26, where 
PKC-ι is located, is an amplicon and that gene amplification 
of PKC-ι is associated with non-small cell lung cancer and 
esophageal squamous cell carcinoma (23,36). Studies have 
also shown that PKC-ι is co‑amplified with neighboring gene 
SRY‑box 2 (37). These findings have clinical ramifications as 
the increased expression of PKC-ι has been shown to correlate 
with poor prognosis in other types of cancer (32,34). The 
results of the present study suggest that prostate cancer behaves 
similarly and that increased expression of PKC-ι indicates a 
less favorable prognosis.
Although PKC-ι has been previously shown to be involved 
in the survival of the normal RWPE-1 cell line, these results 
were observed following serum starvation (38). As PKC-ι is 
activated under stress, for example, following the addition of 
TNF-α or serum starvation, and the results from the tissues 
were so different, the present study examined the reliance 
of cultured cell lines on PKC-ι without serum starvation. It 
was found that PKC-ι had a significant effect in PC cells, but 
had minimal effect in normal cells. This provided evidence 
of the dependence of PC on PKC-ι and assists in explaining 
its overexpression in PC cells. As PKC-ι can be a predictor 
for PC (37) and is also an anti-apoptotic factor (39), resistance 
to apoptosis is decreased by inhibiting PKC-ι. The results of 
the present study showed that inhibitors, including ICA-1, may 
not be directly toxic to cancer cells; however, by inhibiting 
PKC-ι, carcinoma cells that overexpress and rely on PKC-ι 
are profoundly affected. The WST-1 results demonstrated that 
the inhibitors had a cytostatic effect on the PC cells thereby 
inhibiting their growth, differentiation and proliferation prior 
to the induction of apoptosis.
It is suggested that PKC-ι phosphorylates IKK, which in 
turn releases the inhibitor IκBα from NF-κB, allowing NF-κB 
to translocate to the nucleus as a transcription factor known to 
propagate cancer (Fig. 7). A previous study linked the activa-
tion of IKK through the action of PKC (38). The present study 
showed that the phosphorylation of IKKα/β decreased upon 
inhibition of PKC-ι, which decreased the phosphorylation of 
IκBα and prevented its degradation by the release of activated 
NF-κB, allowing it to translocate into the nuclei. These data 
suggest that, by inhibiting PKC-ι, the transcription factor 
NF-κB remained inhibited, and the chain of events was not 
set in motion. NF-κB is generally released during periods of 
stress and is not the only pro-survival factor affecting the cell. 
However, this pathway inhibition may explain the decrease 
in cell growth rates for the two cell lines treated with PKC-ι 
inhibitors. In neuroblastoma cells, ICA-1 has been shown to be 
a specific inhibitor to PKC‑ι, and its inhibition has been shown 
to induce apoptosis (24). In the present study, the DU-145 cells 
also showed signs of increased apoptotic markers and retarded 
growth rate. The PC-3 cells showed a similar decrease in 
growth rate and were subject to apoptotic factors despite their 
aggressive nature. One limitation of the present study was the 
sample size of patient tissues used. A larger sample combined 
with the in vivo assessment of the inhibitors is recommended.
In conclusion, the results in the present study suggested 
that aPKCs are major components responsible for inducing 
cell growth, differentiation and survival in human PC cells. In 
addition, PKC-ι was found to be involved in the activation and 
nuclear translocation of NF-κB. The results also suggested that 
ICA-and ACPD were effective aPKC inhibitors in PC cells and 
did not affect normal prostate epithelial cells at the optimal 
working concentrations for PC cells used. These inhibitors 
reduced cell proliferation and induced the apoptosis of PC 
cells. Taken together, these results indicate that the detection 
of PKC-ι may be used as a predictor of prostate carcinogenesis 
and suggest that patients with PC may benefit from anti‑PKC‑ι 
therapy.
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